Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Development of Prostate Cancer Dendritic Cell Vaccines
NCT07068555Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Adverse Events at 1 month. Started Jun 2025; status: terminated.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07068555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068555.